Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency. Lonapegsomatropin is a prodrug of somatropin.
Lonapegsomatropin was approved for medical use in the United States in August 2021, and in the European Union in January 2022.
Medical uses Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.
History The US Food and Drug Administration granted the application for lonapegsomatropin orphan drug designation.
References
Further reading
External links